Retinalamin in ophthalmology: a review of the effects

Numerous publications have documented the results of clinical trials investigating the use of Retinalamin in patients with various optic nerve and retinal diseases. Retinalamin has been shown to have therapeutic effects when administered by various routes at a dose of 5–10 mg for 10 days. Positive effects have been documented with Retinalamin delivered parabulbarly, subconjunctivally, into the sub-Tenon’s space, endolymphatically, intramuscularly, and by endonasal electrophoresis. To document the effects, the authors used the results of visometry, perimetry, regional ocular hemodynamic studies, and objective electrophysiological and morphometric study parameters. The most methodologically sound clinical trial designs and a high methodological standard characterize studies investigating the effects of Retinalamin in patients with open-angle glaucoma and age-related macular degeneration. A shortcoming of many other studies is the absence or insufficiently designed control group, which reduces the significance of the obtained results. Increased efficacy of Retinalamin has been noted when used in combination with other treatment methods. Given this, it is advisable to focus research on two areas: small, well-designed, clearly defined studies with a limited objective, supported by a strong evidence base, and fundamental research into the mechanisms of Retinalamin’s effects on retinal metabolism, structure, and function.